<DOC>
	<DOCNO>NCT01325571</DOCNO>
	<brief_summary>To evaluate efficacy safety tacrolimus capsule patient myasthenia gravis inadequately treat glucocorticoid .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Tacrolimus Capsules Patient With Myasthenia Gravis</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>diagnose myasthenia gravis ( MG ) clinical diagnosis QMG score ≥7 time enrollment basic treatment drug mainly glucocorticoid , efficacy glucocorticoid therapy sufficient receive blood purification therapy immunoglobulin therapy within 8 week study QMG swallow function score ≥ 2 point QMG vital capacity = 3 abnormal hepatic function uncontrolled diabetes patient hyperkalemia patient immunoinhibitors forbid due malignancy , history malignancy history HIV infection patient allergic Tacrolimus macrolide antibiotic receive immunoinhibitors within 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>prograf</keyword>
	<keyword>immunosuppressant</keyword>
</DOC>